Biomimetic Materials Emerge as the Next Big Trend: How SiYuan Medical Is Taking the Lead

In recent years, medical-grade biopolymer materials have been widely applied in the field of medical devices. While “regenerative materials,” represented by poly-L-lactic acid (PLLA) fillers (commonly known as “baby face needles”), remain highly popular, “biomimetic materials”—specifically silk fibroin—are also garnering increasing attention from both the market and consumers.

Fibroin is the primary component of silk and a natural high-molecular-weight block copolymer composed of 18 amino acids. Amino acids with small side groups, such as glycine, alanine, and serine, are arranged in specific sequences to form relatively regular chain segments that constitute the crystalline regions, providing the basis for the high mechanical strength of fibroin. In contrast, amino acids with bulky side groups, such as phenylalanine, tyrosine, and tryptophan, make up the amorphous regions, endowing fibroin with high elasticity and toughness.

Meanwhile, silk fibroin also exhibits excellent biocompatibility, bioactivity, and tunable biodegradability. Therefore, it has extensive application potential in the healthcare sector, particularly in areas such as medical aesthetics and wound repair.

It is reported that, as a biomaterial, silk fibroin has well-established technologies and a long history of research and development in the medical field, with continuous emergence of clinical achievements in areas such as bone tissue engineering scaffolds, vascular regeneration, and nerve repair. However, its application in the medical aesthetics sector is only just beginning to gain prominence.

This indicates that the competitive landscape of the silk fibroin market in medical aesthetics has not yet clearly taken shape. Such a vast blue-ocean market naturally attracts a cohort of leading enterprises specializing in the research, development, and manufacturing of biomaterials, among which is Nanjing Siyuan Medical Technology Co., Ltd.

Siyuan Medical is among the earliest companies in China to explore the production of silk fibroin raw materials and medical devices. After years of industrial accumulation and technological breakthroughs, it has now established the capability to produce high-quality silk fibroin raw materials. Meanwhile, Siyuan Medical precisely focuses on the medical aesthetics industry, promoting the application of silk fibroin in this field.

Siyuan Medical has not only implemented standardized control over silk fibroin raw materials but also achieved breakthroughs in technical processes.

Specifically, in terms of technological R&D, Nanjing Siyuan Medical Technology Co., Ltd. has overcome production technology barriers and accelerated the development and application of silk fibroin in medical aesthetic products. Furthermore, the company has proactively positioned itself in the raw material market by making its mass-produced silk fibroin ingredients available to external partners, thereby breaking supply constraints and contributing to the development of China’s silk fibroin industry.

In terms of technological breakthroughs, Nanjing Siyuan Medical Technology Co., Ltd. has overcome industry pain points, including the difficulty in precisely controlling the molecular weight of silk fibroin and its poor water solubility. By replacing traditional dialysis processes with advanced ultrafiltration technology, the company has shortened production cycles, significantly increased production capacity, and addressed market issues of limited supply and high prices.

With the support of automated hollow-fiber membrane ultrafiltration equipment, Siyuan Medical has reduced the risk of contamination from human intervention, thereby lowering microbial limits and endotoxin levels in its products. VCBeat has learned that the endotoxin content in the silk fibroin produced by Siyuan Medical can be controlled to within 0.05 EU/mg, meeting the usage standards for implantable medical devices and ensuring the biological safety of its products.

In terms of production management, since silk fibroin is derived from natural silk or cocoons, it requires risk control as an animal-derived material. Therefore, Siyuan Medical imposes strict requirements on silkworm seed farms, mulberry orchards, and the sericulture process, embedding the medical device quality management system into every stage of cultivation.

Meanwhile, throughout the production process, Nanjing Siyuan Medical Technology Co., Ltd. strictly adheres to standardized operating procedures and relevant technical regulations for medical devices, ensuring that the silkworm rearing process is free from the risk of disease contamination. The processing of silkworm cocoons also follows relevant standards to ensure that medical-grade silkworm cocoons comply with the "Guiding Principles for Registration Application Materials of Animal-Origin Medical Device Products" and the YY/T 0771 series of standards for animal-origin medical devices.

It is precisely due to rigorous multi-dimensional quality control that the silk fibroin prepared by Siyuan Medical features high stability, high consistency, low endotoxin levels, and excellent biocompatibility.

VCBeat has learned that Nanjing Siyuan Medical Technology Co., Ltd. (Siyuan Medical) has developed relevant products based on different usage scenarios and needs in the field of medical-device-grade regenerated silk fibroin, and is currently advancing the regulatory submission process in an orderly manner.

In the realm of Class III medical device-grade implantable regenerated silk fibroin formulations, silk fibroin, as a natural "biomimetic" product, offers superior safety and efficacy. It achieves the dual effects of immediate filling and induction of collagen regeneration, enabling long-term tissue replacement. As an upgraded iteration over hyaluronic acid products, it is poised to replace hyaluronic acid in the market and become the next generation of dermal fillers for medical aesthetics.

In response, Nanjing Siyuan Medical Technology Co., Ltd. has conducted refined design and targeted development of silk fibroin based on the specific requirements for solubility, molecular weight, and microbial control across different types of medical devices. The resulting product is applied for injectable filling in the tissue plane between the superficial subcutaneous layer and the deep dermis, aiming to correct wrinkles and provide contouring. According to Nanjing Siyuan Medical, its developed silk fibroin formulation has demonstrated excellent performance in both contouring fill and induction of collagen regeneration.

Furthermore, Siyuan Medical employs a specialized enzymatic hydrolysis process to convert fibroin into silk fibroin peptides of varying molecular weights. Low-molecular-weight silk fibroin peptides exhibit excellent transdermal absorption due to their small size, while high-molecular-weight silk fibroin peptides demonstrate superior film-forming properties and UV-blocking efficacy. In the realm of lifestyle beauty and personal care, these peptides are widely used in products such as facial masks, lotions, serums, sunscreens, and shampoos.

In the silk fibroin market, Nanjing Siyuan Medical Technology Co., Ltd. has taken a proactive lead. While actively responding to national policies, the company continues to innovate, strengthen its core competencies, and enhance its R&D capabilities. By leveraging its end-to-end production technologies and product pipeline, as well as an open supply model, it seeks to engage with more partners. Driven by forward-looking vision and immense potential, Siyuan Medical is propelling the industry forward.

In the future, Siyuan Medical will continue to innovate, strengthen its capabilities, enhance its R&D standards, deepen its market presence, seize current opportunities, and secure future success!